Central Pacific Bank Trust Division Sells 3,366 Shares of Danaher Co. (NYSE:DHR)

Central Pacific Bank Trust Division trimmed its holdings in shares of Danaher Co. (NYSE:DHR) by 35.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,217 shares of the conglomerate’s stock after selling 3,366 shares during the quarter. Central Pacific Bank Trust Division’s holdings in Danaher were worth $1,728,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Belpointe Asset Management LLC raised its stake in shares of Danaher by 26.1% in the 4th quarter. Belpointe Asset Management LLC now owns 5,046 shares of the conglomerate’s stock valued at $1,168,000 after purchasing an additional 1,044 shares during the period. Cetera Advisor Networks LLC raised its holdings in shares of Danaher by 1.9% in the fourth quarter. Cetera Advisor Networks LLC now owns 68,188 shares of the conglomerate’s stock valued at $15,775,000 after purchasing an additional 1,256 shares during the last quarter. Cibc World Markets Corp lifted its position in shares of Danaher by 136.7% in the fourth quarter. Cibc World Markets Corp now owns 85,869 shares of the conglomerate’s stock worth $19,865,000 after purchasing an additional 49,599 shares in the last quarter. Pinebridge Investments L.P. boosted its holdings in Danaher by 29.7% during the fourth quarter. Pinebridge Investments L.P. now owns 48,664 shares of the conglomerate’s stock worth $11,260,000 after purchasing an additional 11,141 shares during the last quarter. Finally, Exencial Wealth Advisors LLC grew its position in Danaher by 0.9% in the fourth quarter. Exencial Wealth Advisors LLC now owns 14,743 shares of the conglomerate’s stock valued at $3,411,000 after purchasing an additional 128 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Wells Fargo & Company initiated coverage on shares of Danaher in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. TD Cowen boosted their price target on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Bank of America increased their price objective on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Evercore ISI upped their price target on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, The Goldman Sachs Group lifted their price objective on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $282.12.

Danaher Stock Down 0.2 %

DHR stock opened at $273.95 on Thursday. The business’s fifty day moving average price is $271.14 and its two-hundred day moving average price is $258.35. The stock has a market capitalization of $202.91 billion, a price-to-earnings ratio of 46.43, a PEG ratio of 4.55 and a beta of 0.83. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the previous year, the company earned $2.05 EPS. The business’s revenue was down 2.9% on a year-over-year basis. On average, equities analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Insider Buying and Selling at Danaher

In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock valued at $11,042,433 in the last three months. Corporate insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.